8-K Announcements
6Material company update
May 6, 2026·SEC
Material company update
May 5, 2026·SEC
Material company update
Apr 27, 2026·SEC
Xencor, Inc.(XNCR)Earnings, Financials & Key Ratios
XNCR•NASDAQ
$13.01
$954M mkt cap·Price updated May 6, 2026
AboutXencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a tumor-targeted antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types; and Tidutamab that is in Phase II clinical trial to treat neuroendocrine tumors. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104 and XmAb841, which are in Phase I clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase I clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; and Novartis XmAb. It develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; VIR-2482 that is in Phase 1/2 clinical trial to trat influenza A; VIR-7832, which is in Phase 1b/2a trial to treat mild-to-moderate COVID-19; and BMS-986414 + BMS-986413 is in Phase 2/3 NIH ACTIV-2 trial in treating COVID-19. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, mild cognitive impairment, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Monrovia, California.Show more
- Revenue$126M+13.7%
- EBITDA-$167M-0.4%
- Net Income-$92M+60.5%
- EPS (Diluted)-1.24+65.4%
- Gross Margin91.63%-8.4%
- EBITDA Margin-132.98%+11.6%
- Operating Margin-141.35%+12.5%
- Net Margin-73.2%+65.2%
- ROE-14.04%+59.5%
- ROIC-16.29%+4.8%
- Debt/Equity0.30-14.2%
- Interest Coverage-1.80+66.7%
XNCR Key Insights
Xencor, Inc. (XNCR) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓High quality earnings: Operating CF exceeds net income
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Negative free cash flow
- ✗Shares diluted 14.1% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
XNCR Price & Volume
Xencor, Inc. (XNCR) stock price & volume — 10-year historical chart
Loading chart...
XNCR Growth Metrics
Xencor, Inc. (XNCR) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years16.29%
5 Years0.47%
3 Years-8.62%
TTM-32.48%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM19.49%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM27.76%
Return on Capital
10 Years-10.07%
5 Years-12.48%
3 Years-19.41%
Last Year-21.59%
XNCR Recent Earnings
Xencor, Inc. (XNCR) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (58%)●Beat Revenue 6/12 qtrs (50%)
Q1 2026Latest
Feb 25, 2026EPS
$0.09
Est $0.64
+85.9%
Revenue
$28M
Est $30M
-5.8%
Q4 2025
Nov 5, 2025EPS
$0.08
Est $0.72
+88.9%
Revenue
$21M
Est $30M
-29.9%
Q3 2025
Aug 6, 2025EPS
$0.41
Est $0.78
+47.4%
Revenue
$44M
Est $24M
+78.9%
Q2 2025
May 7, 2025EPS
$0.66
Est $0.63
-4.8%
Revenue
$33M
Est $22M
+45.5%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q1 2026Latest | Feb 25, 2026 | $0.09vs $0.64+85.9% | $28Mvs $30M-5.8% |
| Q4 2025 | Nov 5, 2025 | $0.08vs $0.72+88.9% | $21Mvs $30M-29.9% |
| Q3 2025 | Aug 6, 2025 | $0.41vs $0.78+47.4% | $44Mvs $24M+78.9% |
| Q2 2025 | May 7, 2025 | $0.66vs $0.63-4.8% | $33Mvs $22M+45.5% |
Based on last 12 quarters of dataView full earnings history →
XNCR Peer Comparison
Xencor, Inc. (XNCR) competitors in Drug Discovery and Antibody Platforms — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 RCUS | 2.62B | 26.00 | -7.90 | -4.26% | -156.36% | -68.97% | 0.16 | |
 MGNX | 190.59M | 3.01 | -2.55 | 0.78% | -49.91% | -120.2% | 0.66 | |
 IMVT | 5.83B | 28.67 | -10.50 | -47.07% | 0.00 | |||
 ALKS | 5.89B | 35.32 | 24.70 | -5.25% | 9.78% | 8.82% | 0.04 | |
 ZYME | 2.05B | 27.61 | -25.56 | 38.87% | -76.56% | -26% | 0.07 | |
 PTGX | 6.63B | 103.97 | -50.72 | -89.41% | -6.48% | -17.76% | 0.02 | |
 ABBV | 362.56B | 204.98 | 86.49 | 8.57% | 6.91% | 62.15% | ||
 REGN | 74.89B | 720.78 | 17.38 | 0.99% | 29.65% | 14.32% | 0.09 |
Compare XNCR vs Peers
Xencor, Inc. (XNCR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
XNCR Income Statement
Xencor, Inc. (XNCR) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 35.71M | 40.6M | 156.7M | 122.69M | 275.11M | 164.58M | 174.62M | 110.49M | 125.58M | 92.84M |
| Revenue Growth % | -59.2% | 13.7% | 285.93% | -21.7% | 124.23% | -40.18% | 6.1% | -36.72% | 13.65% | -32.48% |
| Cost of Goods Sold | 71.77M | 97.5M | 118.59M | 169.8M | 0 | 0 | 0 | 0 | 10.51M | 5.23M |
| COGS % of Revenue | 200.98% | 240.13% | 75.68% | 138.39% | - | - | - | - | 8.37% | - |
| Gross Profit | -36.06M▲ 0% | -56.9M▼ 57.8% | 38.11M▲ 167.0% | -47.11M▼ 223.6% | 275.11M▲ 684.0% | 164.58M▼ 40.2% | 174.62M▲ 6.1% | 110.49M▼ 36.7% | 115.06M▲ 4.1% | 87.61M▲ 0% |
| Gross Margin % | -100.98% | -140.13% | 24.32% | -38.39% | 100% | 100% | 100% | 100% | 91.63% | 94.37% |
| Gross Profit Growth % | -201.16% | -57.78% | 166.98% | -223.61% | 684% | -40.18% | 6.1% | -36.72% | 4.14% | - |
| Operating Expenses | 89.27M | 119.97M | 24.29M | 29.69M | 231.34M | 247.05M | 306.98M | 288.9M | 292.57M | 304.31M |
| OpEx % of Revenue | 249.99% | 295.48% | 15.5% | 24.2% | 84.09% | 150.11% | 175.8% | 261.47% | 232.98% | - |
| Selling, General & Admin | 17.5M | 22.47M | 24.29M | 29.69M | 38.84M | 47.49M | 53.38M | 61.22M | 63.64M | 64.02M |
| SG&A % of Revenue | 49.01% | 55.35% | 15.5% | 24.2% | 14.12% | 28.85% | 30.57% | 55.4% | 50.68% | - |
| Research & Development | 71.77M | 97.5M | 118.59M | 169.8M | 192.51M | 199.56M | 253.6M | 227.69M | 239.43M | 245.53M |
| R&D % of Revenue | 200.98% | 240.13% | 75.68% | 138.39% | 69.97% | 121.26% | 145.23% | 206.06% | 190.67% | - |
| Other Operating Expenses | 4.17M | 8.96M | -118.59M | -169.8M | 0 | 0 | 0 | 0 | -10.51M | -2M |
| Operating Income | -53.56M▲ 0% | -79.37M▼ 48.2% | 13.82M▲ 117.4% | -76.8M▼ 655.5% | 43.77M▲ 157.0% | -82.47M▼ 288.4% | -132.36M▼ 60.5% | -178.41M▼ 34.8% | -177.5M▲ 0.5% | -134.32M▲ 0% |
| Operating Margin % | -149.99% | -195.48% | 8.82% | -62.59% | 15.91% | -50.11% | -75.8% | -161.47% | -141.35% | -144.67% |
| Operating Income Growth % | -337.63% | -48.18% | 117.42% | -655.53% | 156.99% | -288.44% | -60.49% | -34.79% | 0.51% | - |
| EBITDA | -51.53M | -76.12M | 18.12M | -71M | 51.26M | -73.67M | -120.86M | -166.3M | -166.99M | -126.5M |
| EBITDA Margin % | -144.3% | -187.47% | 11.56% | -57.87% | 18.63% | -44.77% | -69.22% | -150.51% | -132.98% | -136.25% |
| EBITDA Growth % | -314.66% | -47.71% | 123.81% | -491.81% | 172.19% | -243.73% | -64.05% | -37.59% | -0.41% | 12.69% |
| D&A (Non-Cash Add-back) | 2.03M | 3.25M | 4.3M | 5.79M | 7.49M | 8.8M | 11.5M | 12.11M | 10.51M | 7.82M |
| EBIT | -42.73M | -79.37M | 13.82M | -76.8M | 82.64M | -54.49M | -113.46M | -198.28M | -57.49M | -18.11M |
| Net Interest Income | 4.18M | 9.09M | 13.62M | 7.26M | 849K | 4.82M | 18.63M | -4.71M | -4.4M | -3.28M |
| Interest Income | 4.19M | 9.1M | 13.62M | 7.26M | 862K | 4.82M | 18.63M | 31.93M | 27.52M | 25.45M |
| Interest Expense | 13K | 16K | 0 | 0 | 13K | 0 | 0 | 36.64M | 31.93M | 18.56M |
| Other Income/Expense | 4.17M | 8.96M | 13.36M | 7.46M | 38.86M | 27.96M | 12.73M | -56.52M | 87.87M | 92.95M |
| Pretax Income | -49.39M▲ 0% | -70.41M▼ 42.6% | 27.19M▲ 138.6% | -69.33M▼ 355.0% | 82.63M▲ 219.2% | -54.51M▼ 166.0% | -119.63M▼ 119.5% | -234.92M▼ 96.4% | -89.42M▲ 61.9% | -170M▲ 0% |
| Pretax Margin % | -138.3% | -173.41% | 17.35% | -56.51% | 30.04% | -33.12% | -68.51% | -212.61% | -71.21% | -183.11% |
| Income Tax | -463K | 0 | 312K | 0 | 0 | 673K | 13.66M | 1.62M | 2.5M | 2.42M |
| Effective Tax Rate % | 0.94% | 0% | 1.15% | 0% | 0% | -1.23% | -11.42% | -0.69% | -2.8% | -1.42% |
| Net Income | -48.92M▲ 0% | -70.41M▼ 43.9% | 26.88M▲ 138.2% | -69.33M▼ 358.0% | 82.63M▲ 219.2% | -55.18M▼ 166.8% | -133.13M▼ 141.3% | -232.62M▼ 74.7% | -91.92M▲ 60.5% | -172.42M▲ 0% |
| Net Margin % | -137% | -173.41% | 17.15% | -56.51% | 30.04% | -33.53% | -76.24% | -210.53% | -73.2% | -185.71% |
| Net Income Growth % | -307.09% | -43.91% | 138.17% | -357.98% | 219.18% | -166.78% | -141.27% | -74.73% | 60.48% | 19.49% |
| Net Income (Continuing) | -38.49M | -70.41M | 26.88M | -69.33M | 82.63M | -55.18M | -133.3M | -236.54M | -91.92M | -172.42M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 337K | -3.58M | 0 | 515.63M |
| EPS (Diluted) | -1.05▲ 0% | -1.31▼ 24.8% | 0.46▲ 135.1% | -1.11▼ 341.3% | 1.37▲ 223.4% | -0.93▼ 167.9% | -2.08▼ 123.7% | -3.58▼ 72.1% | -1.24▲ 65.4% | -2.29▲ 0% |
| EPS Growth % | -287.5% | -24.76% | 135.11% | -341.3% | 223.42% | -167.88% | -123.66% | -72.12% | 65.36% | 27.76% |
| EPS (Basic) | -1.05 | -1.31 | 0.48 | -1.11 | 1.42 | -0.93 | -2.08 | -3.58 | -1.24 | - |
| Diluted Shares Outstanding | 46.82M | 53.94M | 58.47M | 57.21M | 60.5M | 59.65M | 60.5M | 65.04M | 74.24M | 75.25M |
| Basic Shares Outstanding | 46.82M | 53.75M | 56.53M | 57.21M | 58.38M | 59.65M | 60.5M | 65.04M | 74.24M | 75.25M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
XNCR Balance Sheet
Xencor, Inc. (XNCR) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 230.88M | 315.73M | 558.4M | 637.67M | 424.37M | 675.34M | 623.16M | 577.6M | 599.82M | 482.86M |
| Cash & Short-Term Investments | 224.13M | 294.36M | 527.08M | 603M | 334.11M | 623.06M | 593.73M | 497.77M | 547.73M | 384.38M |
| Cash Only | 16.53M | 26.25M | 50.31M | 163.54M | 143.48M | 53.94M | 53.79M | 40.88M | 54.07M | 14.17M |
| Short-Term Investments | 207.6M | 268.12M | 476.77M | 439.46M | 190.63M | 569.12M | 539.93M | 456.9M | 493.66M | 370.21M |
| Accounts Receivable | 1.14M | 10.19M | 24.78M | 23.94M | 66.38M | 29M | 11.29M | 60.85M | 29.3M | 12M |
| Days Sales Outstanding | 11.67 | 91.58 | 57.71 | 71.23 | 88.07 | 64.31 | 23.6 | 201.01 | 85.16 | 108.76 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 5.61M | 804K | 6.55M | 0 | 0 | 23.28M | 18.14M | 18.98M | 22.79M | 86.48M |
| Total Non-Current Assets | 159.22M | 261M | 111.84M | 65.57M | 413.84M | 170.92M | 329.53M | 374.34M | 275.67M | 253.99M |
| Property, Plant & Equipment | 7.09M | 11.81M | 25.18M | 32.28M | 59.97M | 93.6M | 100.12M | 98.14M | 90.9M | 88.31M |
| Fixed Asset Turnover | 5.04x | 3.44x | 6.22x | 3.80x | 4.59x | 1.76x | 1.74x | 1.13x | 1.38x | 1.01x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 11.15M | 11.97M | 14.42M | 15.98M | 16.49M | 18.5M | 18.66M | 18.48M | 8.38M | 7.6M |
| Long-Term Investments | 139.2M | 236.11M | 71.53M | 17.1M | 331.73M | 58.21M | 209.72M | 256.83M | 175.89M | 683.74M |
| Other Non-Current Assets | 265K | 311K | 713K | 212K | 653K | 613K | 1.03M | 885K | 498K | 159.86M |
| Total Assets | 390.1M▲ 0% | 576.73M▲ 47.8% | 670.25M▲ 16.2% | 703.24M▲ 4.9% | 838.21M▲ 19.2% | 846.27M▲ 1.0% | 952.69M▲ 12.6% | 951.95M▼ 0.1% | 875.5M▼ 8.0% | 736.85M▲ 0% |
| Asset Turnover | 0.09x | 0.07x | 0.23x | 0.17x | 0.33x | 0.19x | 0.18x | 0.12x | 0.14x | 0.11x |
| Asset Growth % | -8.97% | 47.84% | 16.22% | 4.92% | 19.19% | 0.96% | 12.58% | -0.08% | -8.03% | -31.81% |
| Total Current Liabilities | 101.34M | 53.85M | 66.56M | 121.06M | 70.74M | 63.84M | 84.71M | 87.43M | 95.91M | 73.46M |
| Accounts Payable | 6.87M | 3.8M | 10.19M | 8.95M | 14M | 10.09M | 13.91M | 16.76M | 10.83M | 7.92M |
| Days Payables Outstanding | 34.93 | 14.21 | 31.36 | 19.25 | - | - | - | - | 375.97 | 808.84 |
| Short-Term Debt | 0 | 0 | 2.17M | 0 | 0 | 0 | 6.33M | 48.45M | 46.53M | 4.03M |
| Deferred Revenue (Current) | 88.81M | 40.08M | 45.2M | 92.61M | 37.29M | 30.32M | 31.68M | 0 | 0 | 0 |
| Other Current Liabilities | 60.3M | 315K | 8.99M | 0 | 0 | 0 | 0 | 0 | 0 | 69.42M |
| Current Ratio | 2.28x | 5.86x | 8.39x | 5.27x | 6.00x | 10.58x | 7.36x | 6.61x | 6.25x | 6.25x |
| Quick Ratio | 2.28x | 5.86x | 8.39x | 5.27x | 6.00x | 10.58x | 7.36x | 6.61x | 6.25x | 6.25x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | -700.09 |
| Total Non-Current Liabilities | 6.71M | 1.2M | 10.49M | 9.74M | 33.97M | 54.93M | 198.85M | 190.49M | 144M | 147.76M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 14.64M | 115.16M | 76.48M | 62.6M |
| Capital Lease Obligations | 0 | 0 | 8.56M | 9.74M | 33.97M | 54.93M | 59.02M | 65.34M | 64.73M | 194.62M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | -4.54M | 1.2M | 0 | 0 | 0 | 0 | 0 | 9.99M | 2.78M | 190.29M |
| Total Liabilities | 108.06M | 55.05M | 77.05M | 130.8M | 104.71M | 118.77M | 283.56M | 277.92M | 239.91M | 221.21M |
| Total Debt | 0 | 0 | 10.73M | 11.63M | 33.97M | 59.63M | 83.43M | 231.95M | 187.75M | 66.63M |
| Net Debt | -16.53M | -26.25M | -39.58M | -151.92M | -109.51M | 5.69M | 29.64M | 191.08M | 133.67M | 52.46M |
| Debt / Equity | - | - | 0.02x | 0.02x | 0.05x | 0.08x | 0.12x | 0.34x | 0.30x | 0.30x |
| Debt / EBITDA | - | - | 0.59x | - | 0.66x | - | - | - | - | -0.53x |
| Net Debt / EBITDA | - | - | -2.18x | - | -2.14x | - | - | - | - | -0.41x |
| Interest Coverage | -3286.69x | -4960.63x | - | - | 6357.23x | - | - | -5.41x | -1.80x | -0.98x |
| Total Equity | 282.05M▲ 0% | 521.68M▲ 85.0% | 593.2M▲ 13.7% | 572.44M▼ 3.5% | 733.5M▲ 28.1% | 727.5M▼ 0.8% | 669.13M▼ 8.0% | 674.03M▲ 0.7% | 635.59M▼ 5.7% | 1.03B▲ 0% |
| Equity Growth % | -10.16% | 84.96% | 13.71% | -3.5% | 28.14% | -0.82% | -8.02% | 0.73% | -5.7% | 52.48% |
| Book Value per Share | 6.02 | 9.67 | 10.15 | 10.01 | 12.12 | 12.20 | 11.06 | 10.36 | 8.56 | 13.71 |
| Total Shareholders' Equity | 282.05M | 521.68M | 593.2M | 572.44M | 733.5M | 727.5M | 668.8M | 677.61M | 635.59M | 515.63M |
| Common Stock | 470K | 563K | 569K | 580K | 595K | 601K | 611K | 703K | 718K | 741K |
| Retained Earnings | -287.29M | -323.28M | -296.4M | -365.74M | -283.1M | -338.29M | -464.37M | -704.04M | -795.96M | -924.88M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -1.81M | -971K | 1.16M | 74K | -1.51M | -6.95M | 1.29M | -663K | 1.58M | 27K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 337K | -3.58M | 0 | 515.63M |
XNCR Cash Flow Statement
Xencor, Inc. (XNCR) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -33.68M | -79.76M | 64.37M | -5M | -16.85M | 24.48M | -77.93M | -202.19M | -135.12M | -135.12M |
| Operating CF Margin % | -94.32% | -196.43% | 41.08% | -4.08% | -6.13% | 14.88% | -44.63% | -182.99% | -107.6% | - |
| Operating CF Growth % | -135.6% | -136.78% | 180.71% | -107.77% | -236.79% | 245.29% | -418.26% | -159.46% | 33.17% | -282.43% |
| Net Income | -48.92M | -70.41M | 26.88M | -69.33M | 82.63M | -55.18M | -133.13M | -236.54M | -91.92M | -172.42M |
| Depreciation & Amortization | 2.03M | 3.25M | 4.3M | 5.79M | 7.49M | 8.8M | 11.5M | 12.11M | 10.51M | 10.39M |
| Stock-Based Compensation | 13.65M | 20.55M | 31.85M | 31.62M | 36.98M | 48.91M | 0 | 53.28M | 43.23M | 40.58M |
| Deferred Taxes | 0 | 0 | 0 | 0 | -18.97M | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 3.32M | 21K | -4.09M | -21.26M | -22.38M | -26.91M | 24.58M | 9.36M | -144.38M | -179.38M |
| Working Capital Changes | -3.76M | -33.17M | 5.44M | 48.18M | -102.6M | 48.87M | 19.13M | -40.4M | 47.45M | 22.18M |
| Change in Receivables | 7.47M | -9.04M | -11M | -185K | -54.94M | 36.86M | 19.83M | -32.67M | 28.73M | 11.13M |
| Change in Inventory | -5.64M | -1.36M | 0 | 0 | 1.4M | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 2.99M | -3.07M | 6.39M | -1.24M | 5.05M | -3.91M | 3.83M | 2.85M | -3.95M | -6.26M |
| Cash from Investing | 31.95M | -164.77M | -50.97M | 100.19M | -46.25M | -119.72M | -110.56M | -7.87M | 139.99M | 152.99M |
| Capital Expenditures | -7.28M | -9.15M | -7.35M | -10.54M | -15.98M | -38.49M | -21.25M | -6.1M | -3.15M | -2.32M |
| CapEx % of Revenue | 20.38% | 22.53% | 4.69% | 8.59% | 5.81% | 23.39% | 12.17% | 5.52% | 2.51% | - |
| Acquisitions | -33.92M | -1.93M | 0 | 0 | -2.66M | 0 | 501K | 0 | 0 | 1.73M |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 33.92M | 2.02M | -3.69M | -3.23M | -3.16M | 90K | 0 | -3.38M | 14.39M | 13.07M |
| Cash from Financing | 3.73M | 254.24M | 10.66M | 18.04M | 43.04M | 5.7M | 188.72M | 197.15M | 8.23M | 7.93M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 0 | 260.25M | 0 | 0 | 28.92M | 0 | 5.39M | 201.26M | 9.96M | 6.98M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 3.73M | -6M | 10.66M | 18.04M | 14.12M | 5.7M | 183.33M | -4.1M | -1.73M | 950K |
| Net Change in Cash | 2M▲ 0% | 9.72M▲ 385.9% | 24.07M▲ 147.6% | 113.23M▲ 370.5% | -20.06M▼ 117.7% | -89.54M▼ 346.3% | -152K▲ 99.8% | -12.91M▼ 8392.1% | 13.1M▲ 201.5% | -25.6M▲ 0% |
| Free Cash Flow | -40.96M▲ 0% | -88.9M▼ 117.0% | 53.34M▲ 160.0% | -18.77M▼ 135.2% | -32.83M▼ 74.9% | -18.92M▲ 42.4% | -96.37M▼ 409.4% | -208.28M▼ 116.1% | -138.27M▲ 33.6% | -188.84M▲ 0% |
| FCF Margin % | -114.7% | -218.96% | 34.04% | -15.3% | -11.93% | -11.5% | -55.19% | -188.51% | -110.11% | -203.4% |
| FCF Growth % | -144.71% | -117.04% | 159.99% | -135.2% | -74.91% | 42.38% | -409.4% | -116.12% | 33.62% | -7.87% |
| FCF per Share | -0.87 | -1.65 | 0.91 | -0.33 | -0.54 | -0.32 | -1.59 | -3.20 | -1.86 | -1.86 |
| FCF Conversion (FCF/Net Income) | 0.69x | 1.13x | 2.40x | 0.07x | -0.20x | -0.44x | 0.59x | 0.87x | 1.47x | 1.10x |
| Interest Paid | 13K | 16K | 11K | 15K | 0 | 13K | 0 | 33K | 0 | 2K |
| Taxes Paid | 969K | 233K | 400K | 0 | 0 | 700K | 0 | 6.1M | 0 | 359K |
XNCR Key Ratios
Xencor, Inc. (XNCR) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -16.42% | -17.52% | 4.82% | -11.9% | 12.65% | -7.55% | -19.06% | -34.64% | -14.04% | -23.68% |
| Return on Invested Capital (ROIC) | -14.22% | -15.65% | 1.98% | -11.83% | 6.29% | -9.12% | -13.87% | -17.11% | -16.29% | -16.29% |
| Gross Margin | -100.98% | -140.13% | 24.32% | -38.39% | 100% | 100% | 100% | 100% | 91.63% | 94.37% |
| Net Margin | -137% | -173.41% | 17.15% | -56.51% | 30.04% | -33.53% | -76.24% | -210.53% | -73.2% | -185.71% |
| Debt / Equity | - | - | 0.02x | 0.02x | 0.05x | 0.08x | 0.12x | 0.34x | 0.30x | 0.30x |
| Interest Coverage | -3286.69x | -4960.63x | - | - | 6357.23x | - | - | -5.41x | -1.80x | -0.98x |
| FCF Conversion | 0.69x | 1.13x | 2.40x | 0.07x | -0.20x | -0.44x | 0.59x | 0.87x | 1.47x | 1.10x |
| Revenue Growth | -59.2% | 13.7% | 285.93% | -21.7% | 124.23% | -40.18% | 6.1% | -36.72% | 13.65% | -32.48% |
XNCR SEC Filings & Documents
Xencor, Inc. (XNCR) SEC filings — annual & quarterly reports (10-K, 10-Q)
XNCR Frequently Asked Questions
Xencor, Inc. (XNCR) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Xencor, Inc. (XNCR) reported $92.8M in revenue for fiscal year 2025. This represents a 1256% increase from $6.8M in 2011.
Xencor, Inc. (XNCR) grew revenue by 13.7% over the past year. This is steady growth.
Xencor, Inc. (XNCR) reported a net loss of $172.4M for fiscal year 2025.
Dividend & Returns
Xencor, Inc. (XNCR) has a return on equity (ROE) of -14.0%. Negative ROE indicates the company is unprofitable.
Xencor, Inc. (XNCR) had negative free cash flow of $188.8M in fiscal year 2025, likely due to heavy capital investments.
Explore More XNCR
Xencor, Inc. (XNCR) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates